Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03163173 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects
A Phase 1 study, sponsored by Galera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03163173 is a Phase 1 study that has completed, run by Galera Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT03163173, a Phase 1 study, has completed, sponsored by Galera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
GC4419 is being studied to treat and prevent oral mucositis (painful inflammation) in cancer patients who receive radiation and chemotherapy. In this study, GC4419 will be mixed with a small amount of radioactive material in order to find out how much study drug is in the blood and to see how the drug is processed and eliminated from the body. The safety and how subjects tolerate the study drug will also be studied.
Interventions
- DRUG GC4419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2017-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03163173
The ClinicalTrials.gov registry entry for NCT03163173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GC4419 is the first listed.
NCT03163173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03163173 about?
NCT03163173 is a clinical study titled "A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects". GC4419 is being studied to treat and prevent oral mucositis (painful inflammation) in cancer patients who receive radiation and chemotherapy. In this study, GC4419 will be mixed with a small amount of radioactive material in order to find out how much study drug is in the blood and to see how the d...
What is the current status of trial NCT03163173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-08-14. Estimated completion is 2017-10-13.
What interventions are being tested in trial NCT03163173?
The interventions under investigation include: GC4419 (DRUG).
Who is sponsoring clinical trial NCT03163173?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.